Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | AOC2 | O75106 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25317589 | 0.87 | KDM1A (0.37) | KCNH2P2RX7 | |
| SCHEMBL15461388 | 0.84 | MAPT (0.35) | DPP4KCNH2P2RX7LMNATP53 | |
| SCHEMBL16037814 | 0.77 | HCRTR2 (0.42) | GAAALDH1A1TSHRMAOA | |
| SCHEMBL25468661 | 0.73 | — | — | |
| SCHEMBL16444624 | 0.72 | SYK (0.33) | P2RX7TP53GAACTSCALDH1A1 | |
| SCHEMBL23189791 | 0.71 | KDM1A (0.31) | — | |
| SCHEMBL23189901 | 0.71 | RORC (0.41) | KCNH2 | |
| SCHEMBL13268545 | 0.70 | CNR2 (0.34) | DPP4P2RX7LMNATP53GAA | |
| SCHEMBL17501454 | 0.70 | AOC2 (0.32) | AOC2MAOA | |
| SCHEMBL1565996 | 0.70 | DPP4 (0.37) | DPP4LMNAAOC2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3613737-B1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2021-12-29 | — | — | EP | disclosed |
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2021-03-23 | — | — | US | disclosed |
| US-20200078343-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | Shanghai Jiongshuo Pharmaceutical Technology Co., Ltd. (CN) | 2020-03-12 | — | — | US | disclosed |
| EP-3613737-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2020-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | CDK9, CDK19, CDK1 | DPP4 2987/4885KCNH2 3700/4885P2RX7 4003/4885 |
| US-20200078343-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | CDK9, CDK19, CDKL1 | DPP4 3355/4885KCNH2 4139/4885P2RX7 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.